DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20191600

Effectiveness of malabaricone-A in P-glycoprotein over-expressing cancer cell lines

Nafisha Yasmin, Alak Manna, Sritama D. Sarkar, Chandrakana Bandyopadhyay, Ajay K. Bauri, Subrata Chattopadhyay, Mitali Chatterjee

Abstract


Background: A major impediment in treatment for cancers is resistance to chemotherapy and is primarily attributed to over-expression of efflux pumps. This study aimed to establish the cytotoxicity of malabaricone-A (MAL-A) in P-glycoprotein/multidrug resistance (P-gp/MDR) over-expressing hematopoietic cancer cell lines.

Methods: Leukemia and multiple myeloma cell lines were indirectly evaluated for their P-gp/MDR status by examining Calcein-AM fluorescence and cell viability was assessed by the MTS-PMS assay.

Results: The fluorescence of calcein was significantly decreased in three cell lines LP-1, RPMI-8226 and CEM-ADR 5000 and reversal with verapamil endorsed their P-gp/MDR activity. The mean IC50 of MAL-A in these MDR+ cell lines (5.40±1.41 to 12.33±0.78 µg/ml) was comparable with the MDR- leukemic (9.72±1.08 to 19.26±0.75 µg/ml) and multiple myeloma cell lines (9.65±0.39 to 18.05±0.17 μg/ml).

Conclusions: Irrespective of their P-gp activity, the cytotoxicity of MAL-A was comparable, making it worthy of future pharmacological consideration in multidrug resistance.


Keywords


Anti-cancer, Calcein, Malabaricone-A, Multidrug resistance MDR, P-glycoprotein

Full Text:

PDF

References


Xia CQ, Smith PG. Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. Mol Pharmacol. 2012;82(6):1008-21.

Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol. 1999;10(6):S53-9.

Patro BS, Tyagi M, Saha J, Chattopadhyay S. Comparative nuclease and anti-cancer properties of the naturally occurring malabaricones. Bioorg Med Chem. 2010;18(19):7043-51.

Manna A, Saha P, Sarkar A, Mukhopadhyay D, Bauri AK, Kumar D, et al. Malabaricone-A induces a redox imbalance that mediates apoptosis in U937 cell line. PLoS One. 2012;7(5):e36938.

Manna A, De Sarkar S, De S, Bauri AK, Chattopadhyay S, Chatterjee M. The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance. Phytomed. 2015;22(7-8):713-23.

Manna A, K Bauri A, Chattopadhyay S, Chatterjee M. Generation of redox imbalance mediates the cytotoxic effect of Malabaricone-A in a multidrug resistant cell line. Anti-Cancer Agents Med Chem. 2015;15(9):1156-63.

Patro BS, Bauri AK, Mishra S, Chattopadhyay S. Antioxidant activity of Myristica malabarica extracts and their constituents. J Agricultural Food Chem. 2005;53(17):6912-8.

Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, et al. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res. 1990;50(21):6793-9.

Homolya L, Holló Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem. 1993;268(29):21493-6.

Holló Z, Homolya L, Davis CW, Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys (BBA)-Biomembranes. 1994;1191(2):384-8.

Homolya L, Hollo M, Müller M, Mechetner EB, Sarkadi B. A new method for quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Brit J Cancer. 1996;73(7):849.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nature Rev Drug Discovery. 2006;5(3):219.

Zahreddine H, Borden K. Mechanisms and insights into drug resistance in cancer. Frontiers Pharmacol. 2013;4:28.

Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, et al. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Res Updates. 2016;27:14-29.

Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in drug resistance in multiple myeloma. Leukemia lymphoma. 2015;56(1):26-33.

Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Multi-drug resistance in cancer. Humana Press. 2010:341-58.

AJ Darby R, Callaghan R, M McMahon R. P-glycoprotein inhibition: the past, the present and the future. Current Drug Metab. 2011;12(8):722-31.

Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010;116(20):4077-85.

Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015;90(11):981-5.